What is Valencell?
Valencell is a pioneer in the development of accurate, intuitive digital health solutions, with a specialized focus on hypertension and chronic disease management. By leveraging a robust portfolio of over 150 patents, the company is transforming the landscape of biometric monitoring. Its flagship innovation, a cuffless blood pressure measuring device, represents a significant shift toward lightweight, portable, and user-centric health tracking. Through seamless integration with mobile applications, Valencell empowers users to engage in proactive health management, effectively bridging the gap between clinical-grade diagnostics and consumer-accessible technology. The company's market position is defined by its deep expertise in sensor analytics and its dedication to improving patient outcomes through reliable, real-time trend tracking.
How much funding has Valencell raised?
Valencell has raised a total of $38.6M across 8 funding rounds:
Series B
$5.5M
Series C
$7M
Private Equity
$2.6M
Series D
$11M
Series E
$10.5M
Debt
$350K
Debt
$647K
Series B (2011): $5.5M led by True Ventures and TDF Ventures
Series C (2014): $7M supported by True Ventures and TDF Ventures
Private Equity (2015): $2.6M, investors not publicly disclosed
Series D (2016): $11M backed by GII Tech, TDF Ventures, and WSJ Joshua Fund
Series E (2018): $10.5M with participation from WSJ Joshua Fund, GII LLC, Sonion a/s, and TDF Ventures
Debt (2020): $350K led by PPP
Debt (2021): $647K supported by PPP
Key Investors in Valencell
TDF Ventures
Founded in 2004 and headquartered in Chevy Chase, Maryland, TDF Ventures is an early stage venture capital firm with offices in Washington DC and Silicon Valley. Focusing on startups that serve enterprise markets within infrastructure, software, and services (IaaS, SaaS, XaaS).
True Ventures
True Ventures is a founder first venture capital firm that partners with creative teams at the earliest stages, providing capital, guidance and a strong community to help build enduring technology and artificial intelligence driven companies.
WSJ Joshua Fund
An institutional investment vehicle that has historically participated in late-stage financing rounds to support the growth of innovative technology companies.
What's next for Valencell?
With the recent strategic investment, Valencell is well-positioned to accelerate the commercialization of its cuffless blood pressure technology. The company's roadmap likely involves expanding its footprint in the enterprise health market, where demand for remote patient monitoring and preventative care solutions continues to surge. By utilizing this capital to refine its sensor analytics and scale manufacturing capabilities, Valencell aims to solidify its leadership in the digital health ecosystem. Future growth will likely be driven by strategic partnerships and the continued integration of its biometric data into broader healthcare infrastructure, ensuring that its technology remains at the forefront of the digital health revolution.
See full Valencell company page
